Literature DB >> 10978169

The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.

D M Walsh1, B P Tseng, R E Rydel, M B Podlisny, D J Selkoe.   

Abstract

The progressive aggregation and deposition of amyloid beta-protein (Abeta) in brain regions subserving memory and cognition is an early and invariant feature of Alzheimer's disease, the most common cause of cognitive failure in aged humans. Inhibiting Abeta aggregation is therapeutically attractive because this process is believed to be an exclusively pathological event. Whereas many studies have examined the aggregation of synthetic Abeta peptides under nonphysiological conditions and concentrations, we have detected and characterized the oligomerization of naturally secreted Abeta at nanomolar levels in cultures of APP-expressing CHO cells [Podlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydell, R. E., Teplow, D. B., and Selkoe, D. J. (1995) J. Biol. Chem. 270, 9564-9570 (1); Podlisny, M. B., Walsh, D. M., Amarante, P., Ostaszewski, B. L., Stimson, E. R., Maggio, J. E., Teplow, D. B., and Selkoe, D. J. (1998) Biochemistry 37, 3602-3611 (2)]. To determine whether similar species occur in vivo, we probed samples of human cerebrospinal fluid (CSF) and detected SDS-stable dimers of Abeta in some subjects. Incubation of CSF or of CHO conditioned medium at 37 degrees C did not lead to new oligomer formation. This inability to induce oligomers extracellularly as well as the detection of oligomers in cell medium very early during the course of pulse-chase experiments suggested that natural Abeta oligomers might first form intracellularly. We therefore searched for and detected intracellular Abeta oligomers, principally dimers, in primary human neurons and in neuronal and nonneural cell lines. These dimers arose intracellularly rather than being derived from the medium by reuptake. The dimers were particularly detectable in neural cells: the ratio of intracellular to extracellular oligomers was much higher in brain-derived than nonbrain cells. We conclude that the pathogenically critical process of Abeta oligomerization begins intraneuronally.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10978169     DOI: 10.1021/bi001048s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  149 in total

Review 1.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

3.  Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization.

Authors:  Rui-Qin Liu; Qing-Hua Zhou; Shang-Rong Ji; Qiang Zhou; Du Feng; Yi Wu; Sen-Fang Sui
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

4.  Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.

Authors:  Sam Gandy; Adam J Simon; John W Steele; Alex L Lublin; James J Lah; Lary C Walker; Allan I Levey; Grant A Krafft; Efrat Levy; Frédéric Checler; Charles Glabe; Warren B Bilker; Ted Abel; James Schmeidler; Michelle E Ehrlich
Journal:  Ann Neurol       Date:  2010-08       Impact factor: 10.422

Review 5.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation.

Authors:  Dominic M Walsh; Matthew Townsend; Marcia B Podlisny; Ganesh M Shankar; Julia V Fadeeva; Omar El Agnaf; Dean M Hartley; Dennis J Selkoe
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

7.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

Authors:  Masashi Kitazawa; Kim N Green; Antonella Caccamo; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

8.  Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility.

Authors:  Li Ling Lee; HyungHo Ha; Young-Tae Chang; Matthew P DeLisa
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

9.  Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides.

Authors:  Xudong Huang; Craig S Atwood; Robert D Moir; Mariana A Hartshorn; Rudolph E Tanzi; Ashley I Bush
Journal:  J Biol Inorg Chem       Date:  2004-11-03       Impact factor: 3.358

10.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.